指南与共识间质性肺疾病

进行性肺纤维化:专家组共识声明

Progressive pulmonary fibrosis: an expert group consensus statement.
指南 / 共识 · Eur Respir J · 2023-03-30

该专家组共识声明强调需标准化进行性纤维化间质性肺疾病(F-ILD)的定义,准确初始诊断对确保恰当初始管理至关重要。鉴于F-ILD表现和进展速率各异,监测和管理须个体化决策。声明还强调诊断检查在风险分层中的价值及个体化监测策略的重要性,并指出在初始管理未能阻止进展后早期使用抗纤维化治疗日益获证据支持。

要点

  • 标准化F-ILD定义,准确初始诊断是恰当管理的前提
  • 监测和管理须基于个体化决策,考虑表现和进展速率差异
  • 初始管理失败后尽早使用抗纤维化治疗,证据日益支持

核心结论

  • 专家组共识提供F-ILD诊断、治疗和监测指导,重点识别进行性肺纤维化(PPF)及管理初始管理后仍进展的肺纤维化。

研究设计与样本

  • 专家组共识声明,基于专家意见形成指导,非系统评价或临床试验。

主要发现

  • 强调标准化F-ILD定义的必要性,准确初始诊断对恰当初始管理至关重要。
  • F-ILD表现和进展速率各异,监测和管理须个体化决策。
  • 诊断检查在风险分层中有价值,逻辑监测策略应针对进展风险管理。
  • 初始管理未能阻止进展后早期使用抗纤维化治疗日益获证据支持。
  • 高分辨率CT分析的人工智能软件尚待验证。

关键数值与推荐

  • PPF应区别于药物性肺毒性或其他形式的急性加重所致的急性恶化。
  • 提供肺康复、氧疗和无创通气的指导,聚焦进展性ILD患者需求。
  • 讨论肺移植转诊标准,并应用于因可及性限制或移植禁忌而不现实的重症患者需求。

临床怎么用

  • 临床中应标准化F-ILD定义,确保准确初始诊断以指导初始管理。
  • 根据患者表现和进展速率个体化监测与管理,使用诊断检查进行风险分层。
  • 初始管理失败后尽早考虑抗纤维化治疗,并区分PPF与急性加重。
  • 对进展性ILD患者提供肺康复、氧疗和无创通气指导,必要时讨论肺移植转诊。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This expert group consensus statement emphasises the need for standardising the definition of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis being of paramount importance in ensuring appropriate initial management. Equally, case-by-case decisions on monitoring and management are essential, given the varying presentations of F-ILDs and the varying rates of progression. The value of diagnostic tests in risk stratification at presentation and, separately, the importance of a logical monitoring strategy, tailored to manage the risk of progression, are also stressed. The term "progressive pulmonary fibrosis" (PPF) exactly describes the entity that clinicians often face in practice. The importance of using antifibrotic therapy early in PPF (once initial management has failed to prevent progression) is increasingly supported by evidence. Artificial intelligence software for high-resolution computed tomography analysis, although an exciting tool for the future, awaits validation. Guidance is provided on pulmonary rehabilitation, oxygen and the use of non-invasive ventilation focused specifically on the needs of ILD patients with progressive disease. PPF should be differentiated from acute deterioration due to drug-induced lung toxicity or other forms of acute exacerbations. Referral criteria for a lung transplant are discussed and applied to patient needs in severe diseases where transplantation is not realistic, either due to access limitations or transplantation contraindications. In conclusion, expert group consensus guidance is provided on the diagnosis, treatment and monitoring of F-ILDs with specific focus on the recognition of PPF and the management of pulmonary fibrosis progressing despite initial management.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Rajan SK, Cottin V, Dhar R, et al. Progressive pulmonary fibrosis: an expert group consensus statement. Eur Respir J. 2023. PMID: 36517177. doi:10.1183/13993003.03187-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。